Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine’s high-affinity blockade at mu-opioid receptors (μORs). Buprenorphine’s partial agonism (low intrinsic efficacy) at μORs can limit the effectiveness of even massive doses once BPOW has begun. Adjunct medications, such as clonidine, are rarely effective in severe BPOW. Ketamine is an N-methyl-D-aspartate receptor antagonist with a potentially ideal pharmacologic profile for treatment of BPOW. Ketamine reduces opioid withdrawal symptoms independently of direct μOR binding, synergistically potentiates the effectiveness of buprenorphine μOR signaling, reverses (resensitizes) fentanyl induced μOR receptor desensitization, and inhibits descending pathways of hyperalgesia and central sensitization. Ketamine’s rapid antidepressant effects potentially address depressive symptoms and subjective distress that often accompanies BPOW. Ketamine is inexpensive, safe, and available in emergency departments. To date, neither ketamine as treatment for BPOW nor to support uncomplicated buprenorphine induction has been described. Case Description: We report a case of an illicit fentanyl-using OUD patient who experienced severe BPOW during an outpatient low-dose cross taper buprenorphine induction (ie, “microdose”). The BPOW was successfully treated in the emergency department with a combination of ketamine (0.6 mg/kg intravenous over 1 hour) combined with high-dose buprenorphine (16 mg sublingual single dose); 3 days later he was administered a month-long dose of extended-release subcutaneous buprenorphine which was repeated monthly (300 mg). At 90 days the patient remained in treatment and reported continuous abstinence from fentanyl use. Conclusions: This single case observation raises important questions about the potential therapeutic role of ketamine as a treatment for BPOW. BPOW is an important clinical problem for which there is currently only limited guidance and no universally accepted approach. Prospective study comparing the effectiveness of differing pharmacologic approaches to treat BPOW is urgently needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent case study found that ketamine may work synergistically with buprenorphine on buprenorphine-precipitated opioid withdrawal due to its unique pharmacological profile that can reduce opioid withdrawal symptoms without direct mu-opioid receptor binding [150]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [150]
Citations
Cites
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 4×
“This single clinical experience raises important efficacy and implementation questions around the possible therapeutic role of ketamine for patients with OUD.”
BackgroundInfluentialGreenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174 · cited 1×
“Successfully overcoming the opioid activation deficit driving BPOW requires surmounting this blockade and may require full agonist doses far outside the range of common clinical practice (eg, 32 mg intravenous [IV] hydromorphone).(12) The clinical limitations of these existing”
Self-citationHigh-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring, A. A., Vosooghi, A. A., Luftig, J., Anderson, E. S., Zhao, X., Dziura, J., Hawk, K. F., McCormack, R. P., Saxon, A., & D’Onofrio, G. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.17128 · Cited by 159 · cited 2×
“) High-dose induction refers to rapidly administering 12–32 mg SL buprenorphine to complete induction within several hours; typically this is only done after abstinence and the development of objective opioid withdrawal.(9) Once BPOW has developed there are 3 general options:(1) stop buprenorphine administration and p…”
MethodSelf-citationPotentiation of μ‐opioid receptor‐mediated signaling by ketamine
Gupta, A., Devi, L. A., & Gomes, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07361.x · Cited by 132 · cited 2×
“Ketamine received Food and Drug Administration approval in 1970 as a dissociative anesthetic and has since been found in animal models and clinical studies to be a potent analgesic, reduce symptoms of acute opioid withdrawal and opioid induced hyperalgesia as well as synergistically potentiate agonist μOR signaling.(1…”
BackgroundProtracted renal clearance of fentanyl in persons with opioid use disorder
Huhn, A. S., Hobelmann, J. G., Oyler, G. A., & Strain, E. C. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108147 · Cited by 112 · cited 1×
“There are growing, if yet not confirmed, concerns that BPOW is more common among fentanyl users.(3) Developing effective treatments for BPOW in people who use fentanyl is critically needed to continue expansion of buprenorphine treatment of OUD as fentanyl becomes the predominate illicit opioid in many communities.”
BackgroundManaging Opioid Withdrawal in the Emergency Department With Buprenorphine
Herring, A. A., Perrone, J., & Nelson, L. S. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.11.032 · Cited by 107
Self-citationThe Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
Aquino, J. P. D., Parida, S., & Sofuoglu, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01032-7 · Cited by 95 · cited 5×
“It is generally believed that BPOW results from abrupt displacement of residual full agonist opioid from mu-opioid receptors (μORs) by buprenorphine, which binds tightly to μORs but with low intrinsic efficacy, causing a sudden drop in opioid activation that is experienced aswithdrawalwith rhinorrhea, body aches, anxi…”
BackgroundInfluentialMethod for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone
Antoine, D., Huhn, A. S., Strain, E. C., Turner, G., Jardot, J., Hammond, A. S., & Dunn, K. E. (2021) · The American Journal on Addictions · doi:10.1111/ajad.13069 · Cited by 94 · cited 2×
“D espite being a rare occurrence, concern for buprenorphine precipitated withdrawal (BPOW) is a barrier to adoption of buprenorphine by clinicians and acceptance by opioid use disorder (OUD) patients.(1,2) The staggering rise in fentanyl related deaths—a 29 fold increase from 2012 to 2020—brings new urgency to the nee…”
BackgroundSnyder, H., Kalmin, M. M., Moulin, A., Campbell, A., Goodman-Meza, D., Padwa, H., Clayton, S., Speener, M., Shoptaw, S., & Herring, A. A. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.05.024 · Cited by 91 · cited 3×
“Safety-net EDs reach the most vulnerable OUD patients for whom the therapeutic benefits of ketamine might be most impactful and for whom early buprenorphine discontinuation likely possess the highest risks of subsequent return to use and overdose.(4) EDs in the US have demonstrated a broad interest in improving care f…”
BackgroundSelf-citationThe epidemic of fentanyl misuse and overdoses: challenges and strategies
Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20846 · Cited by 89 · cited 1×
“Developing effective treatments for BPOW in people who use fentanyl is critically needed to continue expansion of buprenorphine treatment of OUD as fentanyl becomes the predominate illicit opioid in many communities.(4,5) BPOW is an unpleasant physical and psychological experience sometimes observed in physically-depe…”
Background
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“A recent case study found that ketamine may work synergistically with buprenorphine on buprenorphine-precipitated opioid withdrawal due to its unique pharmacological pro fi le that can reduce opioid withdrawal symptoms without direct mu-opioid receptor binding [150].”
BackgroundWeimer, M. B., Herring, A. A., Kawasaki, S. S., Meyer, M. C., Kleykamp, B. A., & Ramsey, K. S. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001202 · Cited by 94
Self-citationA Neuropharmacological Model to Explain Buprenorphine Induction Challenges
Greenwald, M. K., Herring, A. A., Perrone, J., Nelson, L. S., & Azar, P. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.05.032 · Cited by 65
“12 Annals of Emergency Medicine successful is unknown; a case of delayed microdosing failure was recently published, highlighting this uncertainty.(72) Successful induction depends on buprenorphine agonist signaling and reversal of tolerance to the prior opioid.”
BackgroundSelf-citationSchoenfeld, E. M., Westafer, L. M., Beck, S. A., Potee, B. G., Vysetty, S., Simon, C., Tozloski, J. M., Girardin, A. L., & Soares, W. E. (2022) · Academic Emergency Medicine · doi:10.1111/acem.14507 · Cited by 32
Spadaro, A., Faude, S., Perrone, J., Thakrar, A. P., Lowenstein, M., Delgado, M. K., & Kilaru, A. S. (2023) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12880 · Cited by 30
Metadata
- Authors
- Hailozian, C., Luftig, J., Liang, A., Outhay, M., Ullal, M., Anderson, E. S., Kalmin, M., Shoptaw, S., Greenwald, M. K., & Herring, A. A.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Corresponding author
- Herring, Andrew A.
- Venue
- Journal of Addiction Medicine
- Published
- 2021-11-16
- Volume
- 16
- Issue
- 4
- Pages
- 483-487
- ISSN
- 1932-0620 (ISSN-L)
- OpenAlex
- W3213991078
- Cited by
- 38
- References
- 20
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 8 · 2023: 13 · 2022: 6
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- ketamine, buprenorphine, NMDA receptor antagonists, opioid withdrawal treatment, opioid use disorder, emergency department care
- MeSH terms
- Analgesics, Opioid, Buprenorphine, Fentanyl, Humans, Ketamine, Male, Opioid-Related Disorders, Narcotics, Prospective Studies, Substance Withdrawal Syndrome, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use. https://app.cochat.ai/papers/10.1097/adm.0000000000000929
- The paper
- Hailozian, C., Luftig, J., Liang, A., Outhay, M., Ullal, M., Anderson, E. S., Kalmin, M., Shoptaw, S., Greenwald, M. K., & Herring, A. A. (2022). Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.